Immediate Impact
64 standout
Citing Papers
Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer
2025 Standout
Targeting KRAS: from metabolic regulation to cancer treatment
2025 Standout
Works of Shuta Ohara being referenced
KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments
2021 Standout
Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study
2018
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Shuta Ohara | 396 | 310 | 287 | 35 | 595 | |
| Masaya Nishino | 399 | 294 | 289 | 46 | 643 | |
| Shinji Nakamichi | 256 | 273 | 229 | 49 | 539 | |
| N. B. Leighl | 554 | 490 | 203 | 32 | 739 | |
| Edna Chow‐Maneval | 470 | 451 | 227 | 24 | 711 | |
| Monica Giovannini | 403 | 466 | 195 | 35 | 720 | |
| Graham Temple | 429 | 438 | 287 | 16 | 710 | |
| Jie‐Tao Ma | 356 | 302 | 192 | 42 | 646 | |
| E. Dalmau | 269 | 244 | 334 | 27 | 675 | |
| Xinmin Zhao | 253 | 345 | 253 | 46 | 640 | |
| K. Park | 623 | 523 | 211 | 25 | 698 |
All Works
Login with ORCID to disown or claim papers
Loading papers...